NASDAQ:OSA ProSomnus (OSA) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free OSA Stock Alerts $0.57 -0.05 (-8.08%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.56▼$0.6250-Day Range$0.49▼$0.8252-Week Range$0.35▼$5.25Volume60,529 shsAverage Volume74,271 shsMarket Capitalization$9.33 millionP/E RatioN/ADividend YieldN/APrice Target$2.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get ProSomnus alerts: Email Address ProSomnus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside310.1% Upside$2.33 Price TargetShort InterestHealthy2.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.95 out of 5 starsMedical Sector181st out of 938 stocksSurgical & Medical Instruments Industry20th out of 97 stocks 3.4 Analyst's Opinion Consensus RatingProSomnus has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.33, ProSomnus has a forecasted upside of 310.1% from its current price of $0.57.Amount of Analyst CoverageProSomnus has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.08% of the float of ProSomnus has been sold short.Short Interest Ratio / Days to CoverProSomnus has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProSomnus has recently decreased by 19.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProSomnus does not currently pay a dividend.Dividend GrowthProSomnus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OSA. Previous Next 2.5 News and Social Media Coverage News SentimentProSomnus has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ProSomnus this week, compared to 1 article on an average week.Search Interest3 people have searched for OSA on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProSomnus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of ProSomnus is held by insiders.Percentage Held by Institutions70.03% of the stock of ProSomnus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About ProSomnus Stock (NASDAQ:OSA)ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolarygologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.Read More OSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OSA Stock News HeadlinesMarch 28, 2024 | investorplace.comOSA Stock Earnings: ProSomnus Misses EPS, Beats Revenue for Q4 2023March 27, 2024 | finance.yahoo.comQ4 2023 Prosomnus Inc Earnings CallMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 26, 2024 | globenewswire.comProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 19, 2024 | americanbankingnews.comProSomnus (OSA) to Release Quarterly Earnings on TuesdayMarch 15, 2024 | globenewswire.comProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update CallFebruary 23, 2024 | msn.comProSomnus reports pilot study data for remote OSA monitoring deviceFebruary 23, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)March 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 22, 2024 | finance.yahoo.comProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep ApneaFebruary 22, 2024 | globenewswire.comProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep ApneaFebruary 20, 2024 | finance.yahoo.comProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024January 30, 2024 | finance.yahoo.comProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDAJanuary 29, 2024 | finance.yahoo.comProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA DevicesJanuary 23, 2024 | benzinga.comProSomnus Stock (NASDAQ:OSA) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep ApneaDecember 20, 2023 | morningstar.comProSomnus Inc OSADecember 19, 2023 | msn.comWhy Is Sleep Devices Focused ProSomnus Stock Soaring Today?December 19, 2023 | finance.yahoo.comProSomnus Treatment for Sleep Apnea Effective, Study ShowsDecember 19, 2023 | finance.yahoo.comData Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance DevicesNovember 12, 2023 | benzinga.comProSomnus Stock (NASDAQ:OSA), Analyst Ratings, Price Targets, PredictionsNovember 11, 2023 | msn.comCraig-Hallum Downgrades ProSomnus (OSA)November 9, 2023 | finance.yahoo.comProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comProSomnus Announces Third Quarter 2023 Investor Call and Business UpdateOctober 3, 2023 | finance.yahoo.comProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities ConferenceSeptember 27, 2023 | msn.comRoth MKM Maintains ProSomnus (OSA) Buy RecommendationSeptember 26, 2023 | markets.businessinsider.comRoth MKM Maintains Buy Rating for ProSomnus: Here's What You Need To KnowSee More Headlines Receive OSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProSomnus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:OSA CUSIPN/A CIK1934064 Webwww.ProSomnus.com Phone844-537-5337FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Target$2.33 High Stock Price Target$4.00 Low Stock Price Target$1.00 Potential Upside/Downside+278.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,140,000.00 Net Margins-58.65% Pretax Margin-58.65% Return on EquityN/A Return on Assets-69.11% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.38 Sales & Book Value Annual Sales$19.39 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value($1.28) per share Price / Book-0.48Miscellaneous Outstanding Shares16,400,000Free Float15,136,000Market Cap$10.11 million OptionableNot Optionable Beta0.22 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Leonard Liptak (Age 49)Co-Founder, CEO & Director Comp: $965.35kMr. Sung Kim (Age 42)Co-Founder & CTO Comp: $454.63kMs. Laing F. RikkersCo-founder & Executive ChairmanMr. Brian B. Dow (Age 55)Chief Financial Officer Dr. John E. Remmers M.D.Chief ScientistMs. Heather WhalenVice President of Global Marketing ServicesDr. Shouresh Charkhandeh D.D.S.Global Scientific Committee ChairMore ExecutivesKey CompetitorsT2 BiosystemsNASDAQ:TTOOIntelligent Bio SolutionsNASDAQ:INBSVapothermNYSE:VAPOBiotricityNASDAQ:BTCYNeuroMetrixNASDAQ:NUROView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 26,200 shares on 3/11/2024Ownership: 0.623%Vanguard Group Inc.Bought 26,200 shares on 2/15/2024Ownership: 0.623%Axxcess Wealth Management LLCBought 21,700 shares on 2/6/2024Ownership: 0.193%View All Institutional Transactions OSA Stock Analysis - Frequently Asked Questions Should I buy or sell ProSomnus stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProSomnus in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OSA shares. View OSA analyst ratings or view top-rated stocks. What is ProSomnus' stock price target for 2024? 4 analysts have issued twelve-month price objectives for ProSomnus' shares. Their OSA share price targets range from $1.00 to $4.00. On average, they predict the company's stock price to reach $2.33 in the next twelve months. This suggests a possible upside of 310.1% from the stock's current price. View analysts price targets for OSA or view top-rated stocks among Wall Street analysts. How have OSA shares performed in 2024? ProSomnus' stock was trading at $0.9802 at the beginning of the year. Since then, OSA stock has decreased by 42.0% and is now trading at $0.5690. View the best growth stocks for 2024 here. Are investors shorting ProSomnus? ProSomnus saw a decline in short interest in March. As of March 15th, there was short interest totaling 123,000 shares, a decline of 19.6% from the February 29th total of 153,000 shares. Based on an average trading volume of 110,300 shares, the days-to-cover ratio is presently 1.1 days. Approximately 2.1% of the shares of the company are sold short. View ProSomnus' Short Interest. When is ProSomnus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our OSA earnings forecast. Who are ProSomnus' major shareholders? ProSomnus' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.62%), Vanguard Group Inc. (0.62%) and Axxcess Wealth Management LLC (0.19%). How do I buy shares of ProSomnus? Shares of OSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OSA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProSomnus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.